The pharmacy chain agreed to resolve a 2024 Justice Department lawsuit accusing it of unlawfully filling controlled substance prescriptions and billing federal programs.
CVS Pharmacy has agreed to pay $315 million to resolve federal allegations that it illegally dispensed opioids and other controlled substances, federal officials announced Tuesday.
The agreement resolves a 2024 lawsuit brought under President Joe Biden’s administration that accused the pharmacy chain of filling illegitimate prescriptions for dangerous drugs and seeking reimbursement from Medicare, Medicaid, and other government health programs, PBS NewsHour reported.
What the government alleged
According to the Department of Justice, CVS pharmacists filled prescriptions between October 2013 and December 2025 that lacked a legitimate medical purpose or fell outside the normal boundaries of professional practice, Fox News reported.
Prosecutors alleged that CVS filled orders for excessive quantities of opioids, permitted early refills, and supplied risky drug combinations. Those mixtures included trinity prescriptions, which pair an opioid with a benzodiazepine and a muscle relaxant. CVS also dispensed drugs ordered by prescribers running known pill mills who wrote high volumes of prescriptions without any legitimate medical reason.
The government claimed that pharmacists at CVS overlooked clear red flags that showed a strong chance the orders were not legitimate. Federal officials said corporate policies contributed directly to the violations, alleging CVS used performance metrics, incentive compensation, and low staffing levels that pushed pharmacists to process orders quickly and prioritized corporate profits over patient safety.
How CVS responded
CVS disputed the allegations brought by the federal government and did not admit any wrongdoing as part of the settlement.
In a statement, CVS pointed to its workforce of more than 27,000 pharmacists, saying they are trained on the safe and appropriate use of all medications. The company said it has implemented programs designed to help staff make sound decisions for their patients. When the lawsuit was filed in 2024, CVS stated that pharmacists were being subjected to vague and shifting practice standards regarding prescription opioids.
Associate Attorney General Stanley Woodward defended the enforcement action in a statement. “Today’s settlement is a significant milestone in the Justice Department’s efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances,” Woodward said.
New rules and DEA oversight
Along with paying $315 million, CVS entered into an agreement with the Drug Enforcement Administration that requires the chain to establish new safeguards for handling controlled substances.
Under that agreement, CVS must set up a hotline where employees and members of the public can report suspected illegal dispensing. The chain must also proactively track dispensing patterns across its pharmacies and create formal procedures to evaluate prescribers suspected of writing unlawful prescriptions.
Assistant Attorney General Brett Shumate, who leads the Justice Department’s Civil Division, stated that the settlement requires the company to “implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate.”
Previous settlements and industry payouts
The $315 million deal adds to a long list of legal penalties against major pharmacy chains, drug distributors, and manufacturers.
Over the past decade, settlements across the industry with governments in the United States have totaled more than $50 billion. Most of that funding is intended to address the addiction crisis, which was tied to over 100,000 deaths in the country during some years before fatalities declined sharply in recent data.
CVS previously agreed to pay nearly $5 billion in 2022 to resolve thousands of opioid claims brought by states, local municipalities, and Native American tribes. The federal government has also reached deals with other pharmacy operators over the past two years, including Walgreens and Walmart, which agreed to a $50 million settlement over its prescription dispensing practices.
